Abstract
We studied the in-hospital outcome of 138 consecutive patients who received abciximab as a "rescue" intervention for complicated coronary angioplasty in a high-risk clinical setting. "Rescue" treatment with abciximab was associated with clinical and angiographic success rates of 83% and 84%, respectively, whereas the risk of bleeding was higher in patients of low body weight.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
MeSH terms
-
Abciximab
-
Angioplasty, Balloon, Coronary / adverse effects*
-
Antibodies, Monoclonal / therapeutic use*
-
Coronary Angiography
-
Coronary Thrombosis / diagnostic imaging
-
Coronary Thrombosis / drug therapy
-
Coronary Thrombosis / etiology
-
Follow-Up Studies
-
Humans
-
Immunoglobulin Fab Fragments / therapeutic use*
-
Middle Aged
-
Myocardial Ischemia / diagnostic imaging
-
Myocardial Ischemia / therapy*
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Postoperative Complications / diagnostic imaging
-
Postoperative Complications / drug therapy*
-
Postoperative Complications / etiology
-
Prognosis
-
Retrospective Studies
-
Safety
-
Thrombolytic Therapy
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Abciximab